Future work should include the evaluation of latent versus active TGF-β pools, as well as endogenous activators such as MMP2, integrins (e.g., αvβ6), or thrombospondin-1, to more precisely model the endogenous regulation of TGF-β activity in the progression of myopia. This evidence concerns the gene MMP2 and myopia.